Company Biography
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies dedicated to the discovery, development, and commercialization of novel first-in-class drugs for the treatment of cancer and other diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with certain blood cancers.
Contact Information
Name
Dawn Desilets
Address
85 Wells Avenue
Ste 210
Newton, MA 02459
Ste 210
Newton, MA 02459
You have chosen to your
information with
Karyopharm Therapeutics, Inc.
Team Members
Dawn Desilets
Karyopharm Therapeutics
Marketing Operations Manager
Bill Ablaschai
Karyopharm Therapeutics
Associate Director, XPOVIO U.S. HCP Marketing
Srinivas Saream
Karyopharm Therapeutics
Associate Director, Marketing
Andrew Holton
Karyopharm Therapeutics
Executive Director, Market Access